A new study has found that B-cell depletion therapy (which destroys autoimmune disease producing B cells) using rituximab has the potential to treat skin lesions in people with severe active cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).

CLE is one of four different types of lupus, and is limited to the skin and can cause many types of rashes and lesions. This study revealed that 61 percent of participants had improved skin lesions one year after treatment, and more than half saw a complete healing of their lesions.

Read more about the study here.